Harry Reeve: Pfizer Shuts Down $1 Billion ADC Development – What’s Next for Oncology Innovation?
Harry Reeve, i-Pharm Consulting, posted on LinkedIn:
“Pfizer Shuts Down $1 Billion ADC Development – What’s Next for Oncology Innovation?
Big news in the biopharma world: Pfizer has pulled the plug on B7H4V, an antibody-drug conjugate (ADC) acquired in its $43 billion Seagen takeover. This decision triggered a $1 billion impairment charge, alongside an additional $200 million charge for another ADC.
Why the Halt?
After clinical data indicated the drug wouldn’t meaningfully outperform standard-of-care chemotherapy for advanced solid tumours, including triple-negative breast cancer, Pfizer chose to discontinue the programme permanently.
A spokesperson confirmed:
‘There have been no new safety signals observed, but FV is unlikely to deliver a meaningful improvement over existing treatments.’
What’s the Impact?
Pfizer’s decision underscores the high stakes in ADC development, where big investments don’t always lead to breakthrough outcomes. However, ADCs remain a hot area in oncology, with companies like Daiichi Sankyo, AstraZeneca, and Gilead making waves.
What do you think this means for the ADC space? Will Pfizer double down on new oncology bets or shift focus elsewhere? Let’s discuss!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023